By 2030, individuals using GLP-1 weight-loss medications are projected to account for 35% of all food and beverage sales in the United States.

According to "GLP-1 Medication Users to Represent 35% of U.S. Food and Beverage Sales by 2030": By 2030, individuals using GLP-1 weight-loss medications are projected to account for 35% of all food and beverage sales in the United States.

The widespread adoption of GLP-1 therapies is driving a structural shift in consumer behavior, characterized by a long-term reduction in total caloric intake.

According to "GLP-1 Medication Users to Represent 35% of U.S. Food and Beverage Sales by 2030": The widespread adoption of GLP-1 therapies is driving a structural shift in consumer behavior, characterized by a long-term reduction in total caloric intake.

Food and beverage manufacturers and retailers must pivot their product portfolios to prioritize smaller portion sizes and nutrient-dense offerings to align with the needs of this demographic.

According to "GLP-1 Medication Users to Represent 35% of U.S. Food and Beverage Sales by 2030": Food and beverage manufacturers and retailers must pivot their product portfolios to prioritize smaller portion sizes and nutrient-dense offerings to align with the needs of this demographic.

The financial impact of this trend is concentrated in the U.S. market, where the combination of high obesity rates and pharmaceutical accessibility is accelerating the transition.

According to "GLP-1 Medication Users to Represent 35% of U.S. Food and Beverage Sales by 2030": The financial impact of this trend is concentrated in the U.S. market, where the combination of high obesity rates and pharmaceutical accessibility is accelerating the transition.

The economic influence of GLP-1 users will serve as a primary catalyst for retail and manufacturing strategy through the end of the decade, necessitating a move away from high-calorie and processed goods.

According to "GLP-1 Medication Users to Represent 35% of U.S. Food and Beverage Sales by 2030": The economic influence of GLP-1 users will serve as a primary catalyst for retail and manufacturing strategy through the end of the decade, necessitating a move away from high-calorie and processed goods.

Back to report

Key Insights

GLP-1 Medication Users to Represent 35% of U.S. Food and Beverage Sales by 2030

Circana~1 min full read

01
By 2030, individuals using GLP-1 weight-loss medications are projected to account for 35% of all food and beverage sales in the United States.
02
The widespread adoption of GLP-1 therapies is driving a structural shift in consumer behavior, characterized by a long-term reduction in total caloric intake.
03
Food and beverage manufacturers and retailers must pivot their product portfolios to prioritize smaller portion sizes and nutrient-dense offerings to align with the needs of this demographic.
04
The financial impact of this trend is concentrated in the U.S. market, where the combination of high obesity rates and pharmaceutical accessibility is accelerating the transition.
05
The economic influence of GLP-1 users will serve as a primary catalyst for retail and manufacturing strategy through the end of the decade, necessitating a move away from high-calorie and processed goods.

That's the gist.

Dive into the full report for the data, charts, and sources behind these takeaways.

Read the full report